TB-500 vs Thymosin Alpha-1

Overview

TB-500 and thymosin alpha-1 are both members of the thymosin family but have completely different functions. TB-500 is a fragment of thymosin beta-4 associated with tissue repair, while thymosin alpha-1 is an immune-modulating peptide with regulatory approval in some countries. Despite sharing “thymosin” in their names, they are distinct molecules.

Key Facts

Aspect	TB-500	Thymosin Alpha-1
Parent Molecule	Thymosin beta-4	N/A (distinct peptide)
Structure	43 amino acids (fragment)	28 amino acids
Primary Function	Tissue repair (claimed)	Immune modulation
FDA Status	Not approved	Not approved (US)
Other Approvals	None	Yes (multiple countries)

Mechanism Comparison

Aspect	TB-500	Thymosin Alpha-1
Primary Target	Actin-binding proteins	Immune cells
Mechanism	Cell migration, angiogenesis	T-cell maturation, NK activation
System Affected	Tissue repair	Immune system
Natural Role	Wound healing (Tβ4)	Thymic hormone

How They Work

TB-500 (Thymosin Beta-4 Fragment):

• Contains active region of thymosin beta-4
• Proposed to regulate actin and cell motility
• May promote cell migration to wound sites
• Claimed angiogenic properties

Thymosin Alpha-1:

• Isolated from thymus gland
• Enhances T-cell function
• Activates dendritic cells
• Modulates innate and adaptive immunity

Evidence Comparison

Aspect	TB-500	Thymosin Alpha-1
Human Trials	None for TB-500	Multiple (approved elsewhere)
Parent Compound Data	Tβ4 has some	Extensive
Regulatory Approval	None	Many countries
Publication Quality	Low	Moderate-High

Thymosin Alpha-1 Approvals

Approved in over 35 countries for:

• Hepatitis B (adjunct therapy)
• Hepatitis C (with other agents)
• Immune deficiency states
• Cancer immunotherapy (adjunct)

Not FDA-approved in the US.

TB-500 Evidence Limitations

• Research extrapolated from thymosin beta-4
• TB-500 specifically has minimal clinical data
• Most claims based on animal/in vitro Tβ4 studies
• No regulatory pathway pursued

Clinical Applications

Use	TB-500	Thymosin Alpha-1
Wound Healing	Claimed (no approval)	Not primary use
Hepatitis	Not used	Approved indication
Cancer Adjunct	Not used	Approved indication
Immune Deficiency	Not used	Approved indication
Recovery (sports)	Off-label claims	Not used

Administration

Aspect	TB-500	Thymosin Alpha-1
Route	Subcutaneous	Subcutaneous
Duration	Variable	Protocol-dependent

Safety Profile

TB-500

Aspect	Information
Human Safety Data	Very limited
Long-term Effects	Unknown
Quality Control	None (gray market)
Serious Concerns	Unknown

Thymosin Alpha-1

Aspect	Information
Human Safety Data	Substantial
Common Side Effects	Injection site reactions
Serious Concerns	Generally well-tolerated
Post-marketing	Years of data internationally

Regulatory Status

Aspect	TB-500	Thymosin Alpha-1
FDA Status	Not approved	Not approved
International	Not approved	Approved in 35+ countries
Brand Names	None	Zadaxin
WADA Status	Prohibited	Not listed
Quality Available	Research chemical	Pharmaceutical grade (some markets)

Quality and Access

Factor	TB-500	Thymosin Alpha-1
US Availability	Research chemical	Not readily available
International	Research chemical	Prescription (where approved)
Quality Control	None	Pharmaceutical (approved markets)
Purity Concerns	Significant	Less in approved markets

Key Differences

Factor	TB-500	Thymosin Alpha-1
Peptide Family	Thymosin beta	Thymosin alpha
Function	Tissue repair (claimed)	Immune modulation
Evidence Level	Moderate	Moderate-high
Regulatory Status	None	Approved (not US)
Quality Available	Poor	Pharmaceutical possible
Primary Use	Sports/recovery claims	Hepatitis, immune support

Common Misconceptions

Misconception: TB-500 and thymosin alpha-1 are related and have similar effects.

Reality: They are completely different peptides:

• Different structures
• Different mechanisms
• Different functions
• Different evidence levels
• Different regulatory status

Summary

• TB-500 is a thymosin beta-4 fragment claimed for tissue repair with minimal human evidence
• Thymosin alpha-1 is an immune modulator approved in many countries for hepatitis and immune conditions
• Despite both being “thymosins,” they have completely different functions
• Thymosin alpha-1 has substantial clinical evidence; TB-500 has very limited data
• TB-500 is a research chemical; thymosin alpha-1 has pharmaceutical-grade availability internationally
• Different regulatory pathways reflect different evidence bases

---

This comparison is for educational purposes only. TB-500 is not approved and sold only as a research chemical. Thymosin alpha-1 is approved in some countries but not the US. Consult a healthcare provider for medical decisions.